FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1880872956> ?p ?o ?g. }

• W1880872956 endingPage "1099" @default.
• W1880872956 startingPage "1091" @default.
• W1880872956 abstract "Aim To optimize the therapeutic efficacy of NS3/4A protease inhibitors, a multicenter prospective study was performed according to an algorithm based on the Adherence, IL-28B Gene Allele and Viral Response Trial (AG & RGT). Methods A total of 340 patients with genotype 1b hepatitis C virus (HCV) showing serum RNA levels of >5 log were enrolled. The duration of ribavirin/pegylated interferon (PEG IFN)-α-2b therapy was prolonged to 48 weeks in patients with unfavorable IL28B alleles showing adherence rates of less than 80% for either drug during the first 12 weeks even if RVR had been achieved, and in those in whom cEVR, but not RVR, was achieved; furthermore, to 72 weeks in those showing partial early viral response. Results The therapeutic outcomes were assessed in 282 patients, and the therapy was set to complete at 24 weeks in 181 patients (64%) and to prolong to 48 weeks or 72 weeks in 71 patients (25%). The former group showed a SVR rate of 84%, while the latter group showed an SVR rate of 69% with a relapse rate of 7%. The SVR rate was 33% in the 30 patients (11%) in whom the therapy had to be discontinued in less than 12 weeks. Thus, the results of intention-to-treat analysis revealed an overall SVR rate of 75%. Multivariate analysis identified prolongation of the duration of therapy as a significant factor associated with SVR. Conclusion Triple therapy yielded a high SVR rate in the AG & RGT trial via attenuation of viral relapse by prolonged ribavirin/PEG IFN-α-2b administration. © 2015 The Japan Society of Hepatology" @default.
• W1880872956 created "2016-06-24" @default.
• W1880872956 creator A5007750921 @default.
• W1880872956 creator A5010716671 @default.
• W1880872956 creator A5027216235 @default.
• W1880872956 creator A5028598605 @default.
• W1880872956 creator A5030468213 @default.
• W1880872956 creator A5036436319 @default.
• W1880872956 creator A5039457097 @default.
• W1880872956 creator A5041304842 @default.
• W1880872956 creator A5050203519 @default.
• W1880872956 creator A5054515498 @default.
• W1880872956 creator A5059237008 @default.
• W1880872956 creator A5068837225 @default.
• W1880872956 creator A5074821766 @default.
• W1880872956 creator A5075549982 @default.
• W1880872956 creator A5089790580 @default.
• W1880872956 date "2015-03-03" @default.
• W1880872956 modified "2023-09-27" @default.
• W1880872956 title "Multicenter prospective study to optimize the efficacy of triple therapy with telaprevir in patients with genotype 1b hepatitis C virus infection according to an algorithm based on the drug Adherence, IL-28B Gene Allele and Viral Response Trial (AG & RGT)" @default.
• W1880872956 cites W1551301313 @default.
• W1880872956 cites W1887558851 @default.
• W1880872956 cites W1978892007 @default.
• W1880872956 cites W1979174109 @default.
• W1880872956 cites W1987584200 @default.
• W1880872956 cites W2026614040 @default.
• W1880872956 cites W2032624194 @default.
• W1880872956 cites W2034665552 @default.
• W1880872956 cites W2071586067 @default.
• W1880872956 cites W2083507900 @default.
• W1880872956 cites W2092646281 @default.
• W1880872956 cites W2100485606 @default.
• W1880872956 cites W2100797437 @default.
• W1880872956 cites W2109307732 @default.
• W1880872956 cites W2119764771 @default.
• W1880872956 cites W2134790296 @default.
• W1880872956 cites W2165880492 @default.
• W1880872956 doi "https://doi.org/10.1111/hepr.12475" @default.
• W1880872956 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25580859" @default.
• W1880872956 hasPublicationYear "2015" @default.
• W1880872956 type Work @default.
• W1880872956 sameAs 1880872956 @default.
• W1880872956 citedByCount "3" @default.
• W1880872956 countsByYear W18808729562015 @default.
• W1880872956 countsByYear W18808729562016 @default.
• W1880872956 countsByYear W18808729562020 @default.
• W1880872956 crossrefType "journal-article" @default.
• W1880872956 hasAuthorship W1880872956A5007750921 @default.
• W1880872956 hasAuthorship W1880872956A5010716671 @default.
• W1880872956 hasAuthorship W1880872956A5027216235 @default.
• W1880872956 hasAuthorship W1880872956A5028598605 @default.
• W1880872956 hasAuthorship W1880872956A5030468213 @default.
• W1880872956 hasAuthorship W1880872956A5036436319 @default.
• W1880872956 hasAuthorship W1880872956A5039457097 @default.
• W1880872956 hasAuthorship W1880872956A5041304842 @default.
• W1880872956 hasAuthorship W1880872956A5050203519 @default.
• W1880872956 hasAuthorship W1880872956A5054515498 @default.
• W1880872956 hasAuthorship W1880872956A5059237008 @default.
• W1880872956 hasAuthorship W1880872956A5068837225 @default.
• W1880872956 hasAuthorship W1880872956A5074821766 @default.
• W1880872956 hasAuthorship W1880872956A5075549982 @default.
• W1880872956 hasAuthorship W1880872956A5089790580 @default.
• W1880872956 hasConcept C11413529 @default.
• W1880872956 hasConcept C126322002 @default.
• W1880872956 hasConcept C142462285 @default.
• W1880872956 hasConcept C188816634 @default.
• W1880872956 hasConcept C203014093 @default.
• W1880872956 hasConcept C2522874641 @default.
• W1880872956 hasConcept C2776408679 @default.
• W1880872956 hasConcept C2776461080 @default.
• W1880872956 hasConcept C2776999253 @default.
• W1880872956 hasConcept C2778159067 @default.
• W1880872956 hasConcept C2780040827 @default.
• W1880872956 hasConcept C41008148 @default.
• W1880872956 hasConcept C71924100 @default.
• W1880872956 hasConcept C90924648 @default.
• W1880872956 hasConceptScore W1880872956C11413529 @default.
• W1880872956 hasConceptScore W1880872956C126322002 @default.
• W1880872956 hasConceptScore W1880872956C142462285 @default.
• W1880872956 hasConceptScore W1880872956C188816634 @default.
• W1880872956 hasConceptScore W1880872956C203014093 @default.
• W1880872956 hasConceptScore W1880872956C2522874641 @default.
• W1880872956 hasConceptScore W1880872956C2776408679 @default.
• W1880872956 hasConceptScore W1880872956C2776461080 @default.
• W1880872956 hasConceptScore W1880872956C2776999253 @default.
• W1880872956 hasConceptScore W1880872956C2778159067 @default.
• W1880872956 hasConceptScore W1880872956C2780040827 @default.
• W1880872956 hasConceptScore W1880872956C41008148 @default.
• W1880872956 hasConceptScore W1880872956C71924100 @default.
• W1880872956 hasConceptScore W1880872956C90924648 @default.
• W1880872956 hasIssue "11" @default.
• W1880872956 hasLocation W18808729561 @default.
• W1880872956 hasLocation W18808729562 @default.
• W1880872956 hasOpenAccess W1880872956 @default.
• W1880872956 hasPrimaryLocation W18808729561 @default.
• W1880872956 hasRelatedWork W1558399493 @default.
• W1880872956 hasRelatedWork W1997514631 @default.
• W1880872956 hasRelatedWork W1998137369 @default.

• next